
GeminiBio Announces Addition to Board of Directors



***Cory Stevenson, former President of the BioProduction division
at Thermo Fisher Scientific joins Board***

Gemini BioProducts Holding, Inc., a portfolio company of BelHealth Investment Partners, LLC, a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson to its Board of Directors.

Mr. Stevenson retired in 2021 from Thermo Fisher Scientific, where he served as the President of the BioProduction Division. Thermo Fisher Scientific is the world's leader in serving science and its BioProduction business produces many of the industry's leading products and technologies. During Cory's tenure, the business grew revenues from \$200 million to over \$2.5 billion annually. Prior to serving as President of the BioProduction Division, Cory served as Group President of Pelican Life Sciences, VP and General Manager of Oncology Pharmaceutical Services at US Oncology, President of Fisher Healthcare, a division of Fisher Scientific, and various positions at Baxter International.

"GeminiBio has built unique production capabilities for a wide array of liquid bioprocessing services and cell culture solutions," said Mr. Stevenson. "I am excited to join forces with BelHealth to help guide GeminiBio through its next growth phase and position the Company as a reliable outsourced partner for these products and services. Market demand for advanced biotherapeutic manufacturing continues to accelerate across the global biotech industry, and many biotech companies are outsourcing the production of a wide array of process liquids so they can improve their focus on the core manufacturing of biotherapeutics."

Harold Blue, Managing Partner of BelHealth and Chairman of GeminiBio said, "I am thrilled to welcome Cory to our Board of Directors at GeminiBio. With his industry experience and guidance, we are confident Cory will bring invaluable contributions and expertise. GeminiBio's expanding manufacturing capabilities create exciting opportunities to partner with biotherapeutic manufacturers. We look forward to utilizing his experience and relationships to better serve customers requiring small and large volumes of critical cGMP process liquids, including media, buffers, and other liquid solutions."

Source: [GeminiBio](#)

Published on : Wed, 14 Sep 2022